Light Chain Bioscience
https://www.lightchainbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Light Chain Bioscience
China Biotech IPO Drought Lingers But HK Sees First Of 2024
Biotech IPOs on the Chinese mainland have dried up since June 2023 due to regulatory tightening, but Hong Kong is still open to listings of pre-revenue ventures and has seen its first offering of this year.
Venture Capital, Private Equity Investors Keep Pumping Cash Into China CGT Space
Among the latest financing deals, advanced therapeutics such as cell and gene therapies (CGT) continued enjoying the spotlight from venture capital and private equity investors in China. Meanwhile, small molecules with novel mechanism of action such as molecule glue stood out from their peers to win investors’ favor.
Refocus On China: Ark Bio Evolves As It Plans Shanghai Listing
Shanghai-based Ark Biosciences has expanded its pipeline from the RSV-targeting drug ziresovir, licensed from Roche, to pediatric and fibrosis treatments, where there are largely untapped opportunities in China. In a strategy shift, the company is betting on the domestic market instead of going global.
Asia Deal Watch: Astellas Expands Protein Degrader R&D Capability With PeptiDream Collaboration
Plus deals involving Santen/Harrow/Visiox, Aurobindo/BioFactura, AFT/Crossject, Imugene/RenovoRx, Biotheus/BioNTech, GeneQuantum/InxMed, ObsEva/Yuyuan, Monopar/National University of Singapore and Doer Biologics/BioNTech.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- NovImmune SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice